ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus
ImmunityBio stock jumped 10.5% Friday, lifted by news the company wrapped up manufacturing engineering for its natural killer cell therapy platform. Shares traded at $8.64 as of 1:21 p.m. EDT, marking an $0.82 gain over Thursday’s close.
